Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHOICES trial of dirocaftor/posenacaftor/nesolicaftor in adults with cystic fibrosis and rare CFTR mutations
NL-OMON59497Phase 3Withdrawn
- Sponsor
- University Medical Center Utrecht
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dirocaftor, Posenacaftor and nesolicaftor in cystic fibrosis (CF) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Average percent predicted FEV1 after 4, 6, and 8 weeks. Planned start Nov 2022; status: withdrawn.
02
Drugs
dirocaftorPosenacaftornesolicaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON59497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59497.